Meet with... DARPA's Biological Technologies Office

Add this event to your calendar:
07/01/2015 09:30 07/01/2015 11:00 America/Los_Angeles Meet with... DARPA's Biological Technologies Office JLABS , 3210 Merryfield Row , San Diego , CA 92121 JLABS San Diego together with Janssen R&D false DD/MM/YYYY

Meet with... DARPA's Biological Technologies Office

JLABS , 3210 Merryfield Row , San Diego , CA 92121

January 07, 2015 from 09:30 AM to 11:00 AM (PST)

$10 - $35

JLABS SAN DIEGO EVENT The Defense Advanced Research Projects Agency (DARPA) recently launched an important initiative for national security, incorporating biology, engineering, and computer science in a single focus. Since 1958, DARPA has been leading efforts to prevent strategic surprise from negatively impacting U.S. national security and creating strategic surprise for U.S. adversaries. As the Department of Defense's (DoD) primary innovation engine, DARPA undertakes projects that are finite in duration, but that create lasting change. DARPA has funded some of the most cutting-edge and highly classified scientific research in the U.S. Their biomedical projects often include efforts to treat battlefield injuries and to boost the physiological capacities of soldiers. The Biological Technologies Office (BTO) has over 20 different active programs to cultivate fundamental research, discoveries, and applications. BTO focus areas include:

  • Restoring and maintaining warfighter abilities
  • Harnessing biological systems
  • Applying biological complexity

DARPA is looking to engage with a wide spectrum of potential collaborators. Leaders from the life science industry, including entrepreneurs, partners and investors, are encouraged to apply today to meet with a representative from DARPA's BTO!

8:30am | Registration and Breakfast
9:00am | Presentation and Q&A
9:45am | Break
10:00am | One-on-one Meetings*

*Companies must have applied ahead of time for a one-on-one meeting. The application period ended December 5th.

About DARPA's Biological Technologies Office (BTO):
The mission of the Biological Technologies Office (BTO) is to foster, demonstrate, and transition breakthrough fundamental research, discoveries, and applications that integrate biology, engineering, and computer science for national security. BTO seeks to establish and invest in new communities of scientific interest at the intersection of traditional and emerging disciplines. Its investment portfolio goes far beyond life sciences applications in medicine to include areas of research such as human-machine interfaces, microbes as production platforms, and deep exploration of the impact of evolving ecologies and environments on U.S. readiness and capabilities. BTO's programs operate across a wide range of scales, from individual cells to complex biological systems including mammalian and non-mammalian organisms and the macro- and micro-environments in which they operate.

DARPA participating Representative:
Geoffrey Ling Geoffrey Ling | Director, Biological Technologies Office at DARPA
Dr. Geoffrey Ling is an authority on traumatic brain injury (TBI), especially as it pertains to the military. He is presently the Deputy Director of the Defense Sciences Office at the Defense Advanced Research Projects Agency (DARPA) and attending neuro critical care physician at Johns Hopkins Hospital. COL (ret.) Ling is recently retired from the US Army. As a military intensive care physician, he deployed with the 44th Medical Command (Airborne) to Afghanistan in 2003 and Baghdad, Iraq in 2005. One of his units in Iraq, the 10th Combat Support Hospital, awarded him the first "Physician of the Month" distinction. In addition, he went on all four Gray Team missions to both Iraq and Afghanistan (2009-2012). The Gray Team was composed of senior military medical officers selected by ADM Mullen, then Chairman of the Joint Chiefs of Staff, to evaluate and recommend improvements to war-theater TBI care. At DARPA, Dr. Ling has created a broad research portfolio that encompasses over $400M in funding. His most prominent programs are the Revolutionizing Prosthesis (RP) and Preventing Violent Explosive Neuro Trauma (PREVENT). RP is an effort to develop a brain controlled robot prosthetic arm for amputees, and it has been featured twice on CBS's "60 Minutes." PREVENT aims to develop new understanding and treatment of blast-induced TBI and has been profiled in major news outlets, including USA Today and the NY Post.

Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and breakfast. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and breakfast will remain open until January 6th (or full).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on December 5th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. All companies accepted for a one-on-one meeting will be notified of acceptance and scheduled meeting time via email.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Poliwogg, and OrbiMed.

JLABS San Diego together with Janssen R&D

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit or follow @JLABS.

Event contact

Related content